Insights & news

Belgium - Publication of Law Increasing Transparency of Market Entry Agreements

  • 17/06/2020
  • Articles

Today’s Belgian Official Journal contains the text of the Law of 4 May 2020 amending Legislative Provisions with regard to the Transparency of Agreements concerning Reimbursable Specialties (Wet van 4 mei 2020 tot wijziging van wettelijke bepalingen voor wat de transparantie van de overeenkomsten inzake terugbetaalbare specialiteiten betreft / Loi du 4 mai 2020 modifiant des dispositions législatives en ce qui concerne la transparence des conventions en matière de spécialités remboursables) (the Transparency Law – see, attachment).
The Transparency Law will increase parliamentary oversight over market entry agreements for reimbursable medicines (see, Van Bael & Bellis Life Sciences News Alert of 21 April 2020). It will enter into force on 27 June 2020 and will apply to market entry agreements entered into after that date.


Key contacts

Related practice areas

Related insights

Sign up for updates
    • 13/07/2020
    • Articles

    Competition Developments in Pharmaceutical Sector - UK Competition and Markets Authority and European Commission

    The pharmaceutical sector continues to draw competition scrutiny across Europe. United Kingdom On 9 June 2020, the Competition and Markets Authority (CMA) concluded its investigation into the supply of fludrocortisone acetate tablets (FAT), a prescription-only medicine indicated for the treatment of primary and secondary adrenal insufficiency, known as Addison’s Disease (see, attached press release). Aspen Pharma (Aspen) of South-Africa, UK based company Amilco and Dutch firm Tiofarma had apparently agreed that Aspen would be the sole supplier of FAT in the UK. Amilco and Tiofarma were promised financial compensation, while Aspen was given free rein which allegedly allowed it to abuse its monopoly position and increase its prices for FAT by up to 1,800%.

    Read more
    • 09/07/2020
    • Articles

    Court of Justice of European Union Is Asked Preliminary Questions on Application of Falsified Medicines

    Attached is a note discussing a German reference for a preliminary ruling seeking clarification from the Court of Justice of the European Union regarding the application of the Falsified Medicines Directive to parallel-traded medicines. A judgment is due in 2021.

    Read more
    • 07/07/2020
    • Articles

    European Medicines Agencies Network Strategy to 2025

    The European Medicines Agency (EMA) and the national competent authorities (NCAs) of the 27 EU Member States in addition to those of Iceland, Liechtenstein and Norway presented on 6 July 2020 a proposed network strategy for tackling healthcare challenges in a rapidly evolving environment (see, attachment). The strategy is supposed to apply until 2025 and stakeholders are invited to submit their comments in response to an online questionnaire by 4 September 2020.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *